AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

February 21, 2019

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Feb 21, 2019--Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m. ET (10:30 a.m. PT) at the Lotte New York Palace in New York City.

About Rainier Therapeutics

Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic bladder cancer. The company’s antibody, vofatamab (formerly B-701), is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and other cancers. For more information, please visit www.rainierrx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005218/en/

CONTACT: Robert Uhl

Westwicke

(858) 356-5932

Robert.uhl@westwicke.comJulie Rathbun

Rathbun Communications

(206) 769-9291

julie@rathbuncomm.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Rainier Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 02/21/2019 07:30 AM/DISC: 02/21/2019 07:31 AM

http://www.businesswire.com/news/home/20190221005218/en